Objective: To process, standardize and assess the Kasisa bhasma formulation. Methods: The Kasisa bhasma (AK1) was processed in strict accordance to Ayurvedic formulary of India. AK1 was characterized physicochemically by FT-IR, TGA, SEM, AFM, XRD and AAS techniques. Formulation was assessed for anti-anemic, hepatoprotective and toxicity potentials using albino rats. The commercially marketed Kasisa bhsma (AK2) formulation was also used for comparative study.
INTRODUCTION
Bhasma, a herbo-mineral Ayurvedic medicine gained its reputation as a very effective formulation against many chronic ailments compromising the aspects of nanotechnology and overcoming the limitations of conventional dosage forms 1 . The bhasma preparation essentially contains a metallic (toxic) element. But the metal in bhasma is processed into a non-toxic and, moreover, therapeutically enriched agent by a so-called traditional process, bhasmikarana. The bhasmikarana process involves two important steps. The first step is shodhana (roasting along herbal juices with continuous stirring) and the second step is maarana which involves bhavana (wet trituration) and puta system of heating. Thus, therapeutic value of metals in the bhasma relates to their ability to modulate them as nontoxic formulations 2 .
Bhasmas are produced by repeated calcinations to obtain them either as ash or metallic nanoparticles with reduced particle size that may facilitate therapeutic moiety to absorb and assimilate into biological circulation.
Bhasmas are usually administered along with milk,
-142 -butter, honey and ghee that make them palatable, eliminating their harmful effects and enhancing their biocompatibility 3 .
Kasisa bhasma, a calcinated iron preparation obtained from Kasisa or Hirakosh (FeSO 4 7H 2 O-vitriol) is primarily used to treat anemia and also as immunomodulatory and dysmenorrhoea. Due to astringent property, it is being used in dysentery, diarrhea, haemorrhage, ulcers and vitiligo conditions 4, 5, 6 . The repeated calcinations of Kasisa impart the quality in resulting bhasma and facilitate particles to undergo submicron size. Best quality bhasma formulations are essentially required to treat the severe anemia and associated disorders. Calcinated formulations containing typically nano-size or submicron-size therapeutic moieties would alter certain immunogenic status by extended distribution phase and, thus, therapeutic outcomes of such bhasma formulations would evidently increase many folds 7 . Therapeutic efficiency of any formulation typically depends on the quality of starting materials and also on the technology adapted for particular formulation. Both these vary over space and finally reflect in the quality of formulation. The wrong and unskilled manufacturing practices pave way to the production of inferior quality products, which reduce efficacy and are devoid of safety. By following precise manufacturing practices with qualified starting materials and validated process, it is possible to minimize the variability in quality and also to prevent the adulteration in most potent heamatogenic formulation, bhasma. In this backdrop, the present research was focused on in-house process of Kasisa bhasma (AK1) with quality standards as per Ayurvedic formulary and on its pharmacological potentials. The commercial Kasisa bhasma (AK2) formulation was also used here for comparison.
Materials and Methods

Chemicalsand Animals:
Ferrous sulphate, a prime ingredient in the preparation of Kasisa bhasma was procured from SD Fine Chem Ltd., Mumbai, India. Commercial sample of Kasisa bhasma and other raw materials were obtained from the local market.
Male weanling Charles Foster strain albino rats weighing 90-100 g and Wistar strain albino rats of either sex (160-180 g) were separately maintained under standard laboratory conditions with 12-12 h light-dark cycle. The animals were fed with standard rat pellet (Lipton, India Ltd.) and ad libitum. The animals were acclimatized to the laboratory conditions for ten days before commencing the experiments. Experimental protocols were authenticated by the Institutional Animal Ethical Committee (Ref. No. IAEC/930/a/06/ CPCSEA).
Experimental
As per traditional bhasmikarana process, in the first step of sodhana process, ferrous sulphate (250 g) was mixed with appropriate volume (~2.5 L) of citrus fruit juice. The resulting mixture was triturated with khalvam to obtain a homogenous paste for a period of 3.5 h. The homogeneous mixture was further undertaken for the second step, maarana process. The mixture was placed in an earthen crucible covered with a lid. The junction was sealed with double folded, clay smeared cloth. The mixture was subjected to heat in an electrical muffle furnace at 650º C for first and second puta in span of 3.5 min. Almost 30 min time was consumed to reach high temperature whereas it took 4 h 30 min to fall to 30ºC. The incineration process was repeated for four more times to obtain the formulation of Kasisa bhasma (AK1) 8 .
Physical standardization
The prepared Kasisa bhasma,AK1, was preliminary analyzed for floating property, fineness, metallic luster, colour, odour, taste, pH, total ash, acid insoluble ash, water soluble ash, loss on drying (LOD) and particle size.
Characterization studies FT-IR analysis
The both AK1 and AK2 bhasmas were analyzed for changes in their chemical integrity by using Perkin-Elmer FTIR spectrophotometer (1600). Each spectrum of bhasma sample was collected from 16 single average scans at a resolution of 4 cm -1 in the absorption region of 600-4000 cm -1 .
Thermogravimetric Analysis (TGA)
The obvious total weight change due to maarana (thermal) process in the bhasma formulations was assessed by NETZSCH Thermoanalyzer (STA-409). The changes in weight of AK1 and AK2 were recorded between temperatures 0 to 900º C.
Scanning Electron Microscopy (SEM)
The ultramicroscopic structures in AK1 and AK2 were examined using a scanning electron microscope (Hitachi S-3000N SEM). The formulations were fixed to a brass specimen club using double sided adhesive tape made electrically conductive by coating in a vacuum with platinum at 15 Ma.
Atomic Force Microscopy (AFM)
The both samples AK1 and AK2 were assessed for nanosized topography using Nanonics Multiview 1000 AFM head with E scanner (Nanonics Imaging Ltd., Israel). Scanning of images was performed by tapping AFM tips at 20 nm and oscillating the cantilever at its free resonance frequency (80 kHz). The exact position of the tip onto the sample was controlled using an inverted microscope (Olympus, Japan) mounted above the AFM. All measurements were performed at 20° C. The AFM images were captured, processed and analyzed with QUARTZ software, version 1.00 (Cavendish Instruments Ltd., UK).
XRD study
The crystallographic structure and crystalline phases of AK1 and AK2 formulations were examined by using an X'Pert Pro (Phillips) X-ray powder diffractometer. The samples diffraction patterns were studied by placing the bhasma samples in conventional cavity mounts and using Ni-filtered, CuKα radiation, a voltage of 40 kV and a current of 30 mA. The instrument was operated in the continuous scan mode over a 2θ range of 10 to 70º.
Atomic Absorption Spectrometric (AAS) analysis
The concentrations of iron and other trace elements present in AK1 and AK2 were assessed using Atomic Absorption Spectrometer (Perkin Elmer, USA). A 10 mg sample of bhasma was digested in 2 ml of aqua-regia and diluted appropriately to required volume. The concentration of iron was calculated by flame AAS.
Pharmacological standardization 2.5.1 Anti-anemic efficacy:
Male weanling Charles Foster strain albino rats were divided into two groups as: (i) anemic and (ii) nonanemic. Animals of anemic group were again subdivided into three groups according to three treatment schedule. Six animals were used in each.
Induction of anemia:
The animals of anemic group were supplied standard agar gel diet 9 . The diet was prepared for every 6 days rationing at a time and ensured that there is no trace of iron by qualitative chemical analysis. Utmost care was taken to avoid additional iron contamination if any by supplying triple distilled water to animals under study. The non-anemic group animals were supplied agar gel diet in combination with a measured amount of ferrous sulfate and free access to tap water.
Phlebotomy:
In anemic group animals, apart from agar gel feeding, anemia was induced by phlebotomy in each rat. In this method animal tail vein was punctured and 0.6 ml of blood was let out. Phlebotomy was carried out on 1, 4, 8 and 10 th day after continuous feeding of the agar gel diet for 15 days 9 .
Treatment schedule: Animals of three anemic groups were treated orally withAK1 (0.02 mg/kg) bhasma formulation in 2% gum acacia suspension, commercial AK2 (0.02 mg/kg) bhasma formulation in 2% gum acacia suspension and 2% gum acacia suspension, respectively. The animals received treatment orally through feeding canula daily from 15 th day after starting of agar gel diet and up to 60 th day. Non-anemic animals were not treated with formulations and were considered as untreated control group. Kaur N (1994) method was adopted to calculate the treatment doses in the study 10 .
Body weight: The change in body weight (in g) of each animal was recorded at 15-day intervals. 
Estimation of hemoglobin:
Estimation of serum iron and total iron binding capacity (TIBC):
Serum iron and TIBC of each animal were estimated spectrophotometrically from the collected serum at 562 nm 13 . 14 Thirty albino rats of Wistar strain were randomly divided into 5 groups, each of six animals. Group 1 animals served as control and animals in group 2 served as untreated group. Both I and II group animals received 3 doses of 5% acacia solution (1 ml/kg, p.o.) at 12 hr intervals. Group II animals received CCl 4 (1.25 ml/kg, i.p.) along with liquid paraffin (1:1) half-an hour after 1 st dose of vehicle. Animals in groups III to III were administered AK1, AK2 and silymarin (reference standard) a oral dose of 0.02, 0.02 and 100 mg/kg, respectively, by gastric intubation with a soft rubber catheter three times, at 0, 12 and 24 hr. CCl 4 was injected intraperitonially 30 min after the 1 st dose. After 36 h of CCl 4 treatment, blood was collected from all rats and serum was separated by centrifugation. Various biochemical parameters were analyzed in serum by auto analyzer (Mispa Excel) such as SGOT, SGPT, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γ-GT), total proteins (TP) and total bilirubin.
Hepatoprotective efficacy
Carbon tetrachloride (CCl 4 )-induced hepatotoxicity in rats
Toxicology and histopathological studies
The acute toxicity of Kasisa bhasma was studied by following OECD-423 guidelines 15 . In this toxicity study, nine female albino rats were randomly divided into 3 groups (control, AK1 and AK2) of each three. Overnightfasted animals of AK1 and AK2 were administered single oral dose of 0.02 mg/kg. The animals were monitored carefully after dosing during first 30 min. Food was withheld for further 3-4 h after administration of AK1, AK2. Treated animals were closely observed for first 4 hr and daily thereafter, for a total of 14 days. As there was no lethality observed at this dose level, the procedure was repeated further dose of 2 mg/kg. The animals were observed for toxicity signs such as salivation, diarrhea, lethargy, sleep and coma and also gross behavioural changes in skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic, central nervous system and motor activity. The animals were sacrificed and their organs were carefully isolated. The tissues of stomach, kidney and liver were fixed in 10 % formalin embedded in paraffin wax. Histological sections were cut at 4-5 µm thickness and stained with hematoxylin-eosin. The photomicrographs of tissues were captured at various magnifications using Zeiss optical microscope (2000-C), with an attached trinocular camera.
Statistical analysis
The significance of differences among the groups was assessed using one-way ANOVA followed by TukeyKramer test for multiple columns comparison. The value p<0.05 was considered as statistically significant.
Results
Physical standardization
Kasisa bhasma, AK1 formulation was produced in strict accordance to the traditional process bhsamikarana. Produced AK1 formulation appeared typically in brick red color, was tasteless and exerted characteristic odour at pH7.4. The AK1 was found floating when sprinkled on the surface of water and entered into the lines of the fingers when rubbed between the fingers thus passing the fineness test. The loss of metallic luster was confirmed when expose shine of meta commercial properties su soluble ash a size of AK1 analyzer.
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Loss of body weight is one of the clinical manifestations in iron deficiency anemia. Increase in the body weight in the animals of treated (anemic) groups could be due to regaining of haemoglobin levels to an extent. Re-establishing haemoglobin occurred due to Kasisa bhasma treatment which has high iron content as noticed from AAS study and, moreover, due to nanocrystalline iron oxide state. Thus, in turn facilitated the increase in serum ferritin levels and are indicative of the total available iron. The results of our study indicated the bhasmas has some role in dissociating the bound iron from serum protein resulting in an increase in iron level in the serum. It is well recognized that in case of irondeficiency anemia the serum proteins bind the free iron, and the binding capacity (TIBC) increases with the progression of the disease 8 . The bhasma formulations have outplayed in dissociation of serum protein-iron complex, thereby in increase in serum iron levels and thus bhasma will help in curing the iron deficiency anemia 2, 18 .
Kasisa bhasma formulations re-established all biochemical parameters which were altered due to hepatocellular damage caused by CCl 4 toxicity. In group III to V animals, reduction of the levels of hepatic enzymes (SGOT, SGPT and ALP) and total bilirubin to the base levels indicates the re-generation process. This could be due to stability of biliary function and also due to the stabilization of endoplasmic reticulum that could stimulate protein synthesis 19, 20 . Histopathological study showed that AK1 and AK2 have good potentials against hepatotoxicity in Wistar rats and the hepatoprotective activity of bhasma is on par with standard drug candidate sylimarin. Additionally, AK1 and AK2 are proven to be safe without leaving any toxicity signs in their gross behavior as well as histopathology of kidney and stomach.
Conclusion
The herbo-mineral formulation, Kasisa bhasma that contains iron as the active ingredient was processed successfully in strict accordance to Ayurvedic formulary of India and evaluated. The nano-size particles-containing bhasma formulations were analyzed by modern analytical techniques in order to specify the criterion for the final product conforming to all the traditional Ayurvedic parameters. The results of the present study revealed that Kasisa bhasma is an efficient iron preparation for the management of iron deficiency anemia. Overall, in-house prepared Kasisa bhasma formulation is very effective against severe anemia and iron deficiency-associated diseases with scientific evidence. Thus, the adapted process in the preparation of AK1, can be exploited for further establishment of validated protocols for Ayurvedic medicines and also as a basis for clinical studies.
